Karen Henn Gil
65  Ergebnisse:
Personensuche X
?
3

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
4

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
5

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
6

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
7

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
8

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
 
?
12

FAK-Mediated Signaling Controls Amyloid Beta Overload, Lear..:

Saleh, Bisan ; Srikanth, Kolluru D. ; Sneh, Tal...
International Journal of Molecular Sciences.  23 (2022)  16 - p. 9055 , 2022
 
1-15